Personal Capital Advisors Corp bought a new position in Abbott Laboratories (NYSE:ABT) in the fourth quarter, Holdings Channel reports. The fund bought 6,175 shares of the healthcare product maker’s stock, valued at approximately $352,000.
Other large investors also recently bought and sold shares of the company. Rowland & Co. Investment Counsel ADV bought a new stake in Abbott Laboratories in the 4th quarter worth approximately $102,000. Tributary Capital Management LLC bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at $106,000. Heritage Trust Co grew its position in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after acquiring an additional 200 shares during the period. Thompson Davis & CO. Inc. grew its position in shares of Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after acquiring an additional 370 shares during the period. Finally, Motco grew its position in shares of Abbott Laboratories by 213.7% during the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 1,962 shares during the period. 70.61% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently issued reports on ABT. Argus boosted their price objective on shares of Abbott Laboratories from $66.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 30th. They noted that the move was a valuation call. Citigroup boosted their price objective on shares of Abbott Laboratories from $59.00 to $64.00 and gave the company a “neutral” rating in a research report on Tuesday, January 30th. Barclays boosted their price objective on shares of Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Guggenheim reissued a “buy” rating and set a $72.00 price objective on shares of Abbott Laboratories in a research report on Thursday, January 25th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $67.00 price objective on shares of Abbott Laboratories in a research report on Thursday, January 25th. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $65.47.
Abbott Laboratories (ABT) opened at $60.17 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a one year low of $42.31 and a one year high of $64.60. The firm has a market cap of $104,731.95, a price-to-earnings ratio of 24.07, a P/E/G ratio of 1.81 and a beta of 1.56.
Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Abbott Laboratories had a net margin of 1.74% and a return on equity of 13.80%. The company had revenue of $7.59 billion for the quarter, compared to analysts’ expectations of $7.38 billion. During the same quarter in the previous year, the company earned $0.65 EPS. Abbott Laboratories’s revenue for the quarter was up 42.3% on a year-over-year basis. research analysts expect that Abbott Laboratories will post 2.86 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.86%. Abbott Laboratories’s dividend payout ratio (DPR) is 430.79%.
TRADEMARK VIOLATION NOTICE: “Personal Capital Advisors Corp Takes $352,000 Position in Abbott Laboratories (ABT)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.chaffeybreeze.com/2018/02/18/personal-capital-advisors-corp-takes-352000-position-in-abbott-laboratories-abt.html.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.